Home › Iron-Deficiency Anemia › NCT06492512

Oral Iron Supplementation on Alternate vs. Consecutive Days for Iron Deficiency Anemia in Pregnancy

Who can join

Ages 18 to 45 · Women

Inclusion Criteria:

* Pregnant patients will be enrolled at less than 30 weeks gestational age (GA) with laboratory confirmed IDA (as defined by hemoglobin under 10.5 g/dL, as well as ferritin under 15 mcg/L)

Exclusion Criteria:

* Patients \<18 years old, patients who have severe IDA that requires blood transfusion or IV iron infusion, patients who have other known hemoglobinopathy (such as thalassemia or sickle cell anemia) or anemia of different mechanism (such as vitamin B12 or folate deficiency), patients with ulcerative colitis, Crohn's disease, gastric ulcers, patients who have previously undergone gastric bypass surgery, patients who experience admission for antepartum bleed, have been diagnosed with abnormal placentation (i.e., placenta previa, placenta accreta, placenta increta or percreta)

About the study

This will be a randomized clinical trial. Enrolled subjects will be randomized (1:1) into two study arms to receive either daily (Group 1) or alternate day (Group 2) supplementation with one oral pill containing ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill.

What is being tested

• daily ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill (drug)
• alternate day ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill (drug)

Sponsor: Southern Illinois University · Participants: 120 · Started: May 27, 2025

Contact the study team

• Kathleen A Groesch, MS · Phone: 217-545-6671
• Teresa S Wilson, BA · Phone: 217-545-6711

Official record on ClinicalTrials.gov — NCT06492512

Locations in the U.S.

Conditions

• Iron-Deficiency Anemia

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.